SCHEMBL1618535

SCHEMBL1618535

COc1cc(-c2noc(C)n2)c(C(=O)Cl)cc1OCc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 2/20 0.45
NPC1 O15118 1/20 0.44
HPGD P15428 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
SRD5A1 P18405 2/20 0.43
SRD5A2 P31213 2/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
MAPT P10636 1/20 0.42
HCRTR1 O43613 1/20 0.41
HCRTR2 O43614 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
CTSV O60911 2/20 0.41
CTSL P07711 2/20 0.41
RXRA P19793 1/20 0.40
BRD4 O60885 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1618359 0.92 SMPD1 (0.48) SMPD1NPC1HPGDRAB9ASMN1; SMN2
SCHEMBL1616923 0.91 SMPD1 (0.46) SMPD1NPC1HPGDRAB9ASMN1; SMN2
SCHEMBL1617930 0.90 ATM (0.47) SMPD1NPC1HPGDRAB9ASMN1; SMN2
SCHEMBL1617879 0.90 SMPD1 (0.47) SMPD1NPC1HPGDRAB9ASMN1; SMN2
SCHEMBL1616506 0.89 NPC1 (0.46) SMPD1NPC1HPGDRAB9ASMN1; SMN2
SCHEMBL1617764 0.88 HTT (0.46) SMPD1NPC1HPGDRAB9ASMN1; SMN2
SCHEMBL12717270 0.88 SMPD1 (0.44) SMPD1NPC1HPGDRAB9ASMN1; SMN2
SCHEMBL8037100 0.88 SMPD1 (0.44) SMPD1NPC1HPGDRAB9ASMN1; SMN2
SCHEMBL12717263 0.87 HPGD (0.44) SMPD1NPC1HPGDRAB9ASMN1; SMN2
SCHEMBL8041151 0.87 SMPD1 (0.43) SMPD1NPC1HPGDRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2246338-B1 NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION KISSEI PHARMACEUTICAL (JP) 2013-11-20 EP disclosed
US-7923462-B2 Catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition KISSEI PHARMACEUTICAL CO., LTD. (JP) 2011-04-12 US disclosed
US-20100280083-A1 NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-11-04 US disclosed
EP-2246338-A1 NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION Kissei Pharmaceutical Co., Ltd. (JP) 2010-11-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280083-A1 NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION COMT, CYP2D6, CYP3A43 SMPD1 2029/4885NPC1 1524/4885HPGD 964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.